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ABSTRACT , , . 
Previous studies have shown that when R-flurbiprofen 
(R-FB) is administered in the Min/+ mouse model it can 
cause the prevention and regression of intestinal tumors. 
To determine the rate and mode of action at which 
preexisting tumors regress, 72-day old Min/+ mice were 
administered R-FB or vehicle control for 0, 4, 10, 21 and 
42 days;. After necropsy tumor loads and apoptotic indices 
(AI) from normal and tumor appearing tissues were obtained. 
The data obtained from.Min/4: mice administered R-FB 
demonst|rated: 1) a steady decrease in the total number of 
developed tumors over time; 2) some involvement of 
increasing the AI in tumor regions, 3) a significant 
increase of the AI in normal appearing crypts of the small 
intestine, and 4) no change in the AI of normal appearing 
villus regions. Increased incidence of apoptosis in the 
crypts of normal appearing tissue may explain the tumor 
prevention activity of R-FB. Although there was some 
evidence of an increased incidence of apoptosis in tumor 
regions there was not an overall decrease in tumor 
diameters. Because of this, the possible roles of 
apoptosis and desquamation in tumor regression remain 
undefined. 
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 CHAPTER:ONE 
INTRODUCTION 
Background 
Colon Canqer 
In the United States there is an .average lifetime risk 
of over 6% for developing colon cancer which is considered 
to be high-risk. These statistics piace coipn cancer as. 
the third most cominon cancer and.the second leading Cause 
of death due to.cancer in the U.S. Each .year an estimated 
15.0,000 people are diagnosed with colon . Cancer and 55,:00O 
people die of this disease. In spite.of the enormous 
efforts to improve treatment and develop cures for advanced 
disease:., the overall mortality rates for most forms.,of 
epithelial cancers,:. ihclading colon cancer, have not . , . 
declined in the past. 25 years (Conley, Kaplan and Arbuck. 
1998 and Hongland Spprn 1997). In light of this 
information much, of current research, is.toe on: genetic, 
and Other risk factors to. uncover the ; 
predisposition Ifor colorectal;cancer in various 
populations. ^ ^ ^ ^ ^ ^ ^ ^^ . 
Cancers, ■including:colorectal cancer, involve mutated 
gehes that, when expressed, produce molecules that 
1 
influen ;e normal cellular activities. Alterations in these 
normal activities can become devastating if they interfere 
with th regulation of cellular growth mechanisms. In 
normal Situations, mutations in the genome occur on a 
regular basis, but are dealt with by mechanisms such as: 
DNA repair, cell cycle arrest, and/or apoptosis.. Although 
DNA repair and cell cycle arrest play an important part in 
salvaging a genetically mutated cell, it is apoptosis which 
acts as the ultimate backup plan by preventing damaged and 
unwanted cells from replicating. Apoptosis or "programmed 
cell death" is a morphologically and biochemically distinct 
form of cell death that can be triggered by a variety of 
extracellular agents. Apoptosis occurs during normal 
development as well as in various adult pathophysiological 
states. Apoptosis plays an important role in organisms as 
a counterbalance to cellular proliferation (McGill and 
Fisher 1997). Cellular proliferation is important to form 
and maintain tissue, but can become harmful if it is not 
balance;d,or held in check by apoptosis. The balance 
between these two processes is vital and the consequences 
of an imbalance can result in the development of cancer 
(Foster 2000). 
Colorectal cancer arises in a multistep fashion.that 
can take 10-15 years in humans. Accumulating mutations in 
several: genes can result in abnormalities of cellular 
growth regulation. These genetic alterations transform the 
normal epithelium into hyperplastic regions, leading to 
adenomai formation and eventually carcinoma (Winawer 1999 
and Marian 1996). During this multistep process in 
colorectal cancer, cells may develop mutations in the 
following key genes: the adenomatOus polyposis coli {APC), 
p53 tumor suppressor genes, the Ras oncogene, and various 
genes that mediate DNA mismatch repair (Shiff and Rigas 
1999). : The ARC gene has beeji considered the "gatekeeper" 
of colonic epithelial cell proliferation, and inactlvation 
of this.gene is required for net cellular proliferation, 
i.e., imbalance with apoptosi.s (Umetani et al. 2000);. In 
the intestine, APC protein levels increase at the c.rypt-
villus boundary where cell migration from the crypt is 
crucial and where cells accumulate during adenoma formation 
(Nathke■et al, 1996) . The APC gene is found to be mutated 
in over. 80% of. sporadic colorectal adenomas and. carcinomas. 
{.Tolinspm, Ilyas and Novelli. 1997.) . The . Pas gene codes . for 
a GT.P-binding protein that functions as a . signal. transducer 
of extracellular stimuli to. regulate cellular proliferation 
and differentiation (Finco et al. 1997). The function of 
the Ras protein is to activate transcription factors 
(i.e. N -kB) and pathways that, in return, influence the 
express>ion of other genes resulting in overall cellular 
survival. Oncogenic mutations in Ras, considered to be 
required for cellular transformation, occur in 50% of 
colorectal tumors, predominately in larger adenomas and 
carcinomas (Finco et al. 1997 and Marian 1996). Another 
gene, p53, also plays a role in cancer development. The 
normal function of p53 involves sequence-specific DNA 
binding that promotes cell-cycle arrest or apoptosis in 
response to a variety of cellular stresses (Lowe 1999). 
Evidence suggests that mutations in p53 lead to a reduction 
of apoptosis and rapid tumor progression (Smith et al. 
1995). In. addition, the gene for p53 is found mutated in 
75% of late stage adenomas of colorectal cancer (Toiinsom, 
Ilyas and Novelli 1997 and Marian 1996). Although there 
are many other genes that are related to colorectal cancer, 
they are less common then APC, Ras and p53 and their roles 
in the piathophysiology of colorectal cancer are still under 
investigation. 
Molecular Targets 
Characterizing cancers for genetic mutations involved 
in carcinogenesis and the altered activities they influence 
have helped researchers discover and/or focus on 
chemotherapeutic agents that are specific for those 
molecular targets. In theory, interfering with the 
activities of genes that are responsible for the loss of 
cellular regulation should restore the ability of affected 
cells to undergo apoptosis (Wang et al. 1999). For 
example, the gene for inducible cyclooxygenase, a key 
enzyme for the formation of prostaglandins from arachidonic 
acid, is overexpressed in most gastrointestinal tumors. 
There are two known isoforms of the cyclooxygenase 
enzyme, cyclooxygenase-1 and -2 (COX-1 and COX-2, 
respectively). The COX-1 enzyme is constitutively 
expressed and is considered to be responsible for the 
prostaglandin synthesis required for physiological or 
"housekeeping" functions of the cell. The COX-2 enzyme, 
although constitutively expressed in selected tissues, is 
inducible by a variety of extracellular and intracellular 
stimuli and is involved in inflammation, mitogenesis and 
specialized signal transduction (Kam and See 2000). In the 
gastrointestinal tract, cyclooxygehase-synthesized 
          
prostaglandins, in particular prostacyclin and PGE2, 
normally act as cytoprotective agents that regulate gastric 
acid and mucus production and vasodilation of the gastric 
' ' i ' • 
mucosa (Kam and See 2000). However, when, the COX-2 gene is 
overexpressed, there by causing prolonged high levels of 
prostaglandins, tumor growth may be promoted. In human 
colorectal carcinomas there is a positive relationship 
between COX-2 expression and the size, invasiveness and 
stage of the carcinoma (Fujita et al. 1998 and Sheehan et 
al. 1999). Although the mechanism for increased COX-2 
expression is not completely understood, it is known that 
oncogenic Ras activates NF-kB, a transcription factor found 
to be responsible for the increased expression of COX-2. 
Increased COX-2 then leads to increased prostaglandin 
synthesis and ultimately inhibition of apoptosis (Mayo et 
al. 1997 and Kojima et al. 2000). Consequently these steps 
are considered as early and central events in colon 
carcinogenesis. Because of the role that COX-2 and NF-kB 
may have in the progression of colorectal adenomas and 
carcinomas, they have become important molecular targets 
for drug development for the prevention and treatment of 
colorectal cancer (Prescott and White 1996 and Hong and 
Sporn 1997). 
Nonsteroidal Anti-Inflammatory Drugs 
Nonsteroidal anti-inflammatory drugs (NSAIDs), 
including aspirin have been used for many years for the 
treatment of inflammatory diseases such as arthritis. . ' 
Numerous reports from human epidemiological studies, animal 
models, and in vitro experiments have all suggested that 
the administration of NSAIDs represents a potential option 
in the chemotherapy and chemoprevention of colorectal 
cancer (Gupta and DuBois 1998). Most NSAIDs are considered 
cox-inhibitors given that they inhibit both COX-1 and COX-2 
to the same degree. However, because these NSAIDs are 
unable to distinguish between the two COX enzymes, 
inhibition of COX-1 leads to the blocking of the 
cytoprotective actions of prostaglandin thus they are 
implicated in gastrointestinal (GI) toxicities involving 
gastric mucosal erosions (Wallace et al. 1998). Because 
traditional NSAIDs exhibit GI toxicities, a new generation 
of NSAIDs "COX-2 inhibitors" was evaluated for the ability 
to selectively inhibit the COX-2 enzyme (Fosslien 2000). 
Although predominately from in vitro and animal studies, 
evidence indicates that these COX-2 inhibitors have 
maintained their anti-neoplastic potential (Kawamori et al, 
1998 and Stolina et al. 2000). However, COX-2 inhibitors 
such as Celecoxib and Vioxx seem to be safer than 
traditional NSAIDs, though clinical trials have 
demonstrated that they are not completely free from GI 
toxicities. Because of the continued GI toxicities, the 
FDA still requires the manufacturers of the COX-2 
inhibitors to carry package warnings similar to the 
traditional NSAIDs (Feldman and McMahon 2000). 
Alternate Mechanism 
Although there is mounting evidence that COX-2 
inhibition plays an important role, in the anti-neoplastic 
effects of NSAIDs, there is also evidence of a second 
mechanism of action. Studies indicated that COX-2 
inhibitors maintain their anti-proliferative activities 
even in colon cancer cell lines that lack COX-1 and COX-2 
expression and therefore lack the ability to produce 
prostaglandins (Smith, Hawcroft and Hull 2000 and Hanif et 
al. 1996). While the alternate mechanism is currently 
unknown it is possible that inactivation of NF-kB could be a 
candidate. 
NF-kB is a ubiquitous, rapid response transcription 
factor that regulates several classes of genes including 
those for cytokines, growth factors, other transcription 
factors and, as previously mentioned, COX-2 (Lee and 
Burckarc 1998 and Kojima et al. 2000). A common theme for 
all of these NF-kB regulated genes is their involvement with 
cellular survival. It appears that NF-kB plays a central 
role in inhibiting apoptosis allowing normal cells to 
progress towards transformation (Martin, Schmid and 
Hofer-Warbinek 1999). It has been shown that some of the 
traditional and COX-2 inhibiting NSAIDs inhibit NF-kB either 
directly or indirectly (Yamamoto et al. 1999). The ability 
of NSAIDs to inhibit a transcription factor, such as NF-kB, 
which has such broad regulatory activities, may be one of 
the reasons NSAIDs also have many potential uses. 
Cyclooxygenase Inhibition 
Several classes of NSAIDs are chiral compounds and 
exist as two enantiomeric forms (R- and S-). 
Representatives of chiral compounds from the propionic acid 
class of NSAIDs are ketoprofen, ketorolac, and 
flurbiprofen. Traditionally, the activity of NSAIDs was 
assessed based on their ability to inhibit the COX enzymes. 
These NSAIDs, in racemic (rac; mixture of both R- and 
S-enantiomers) form, are potent COX inhibitors and are 
extensively used as therapeutic agents for 
anti-inflammatory and analgesic purposes (Carabaza et al. 
1996 and Muller et al. 1990). However, when each 
enantiomer is tested separately it is found that the 
S-enantiomer is predominately responsible for the COX 
inhibiting capabilities (Carabaza et al. 1996). Such is 
the, case for Flurbiprofen (FB), the, R-enantiomer (R-FB) is 
considered a non-COX inhibitor due to its high IC50 
(concentration at which 50% of the enzyme activity is , , 
inhibited) for the COX-1 and COX-2 enzymes (400 nM and 
1400 nM, respectively). While the S- enantiomer of 
Flurbiprofen (S-FB) is vastly more potent than R-FB with an 
IC50 for'COX-l and COX-2 of 2.7 nM and.2.5 nM, respectively 
(Carabaza et al. 1996),. S-FB is 148 and 560,times more 
potent at inhibiting COX-1 and COX-2, respectively, than 
R-FB, and it was for this reason that R-FB was considered 
relatively inactive and was;labeled as a non-COX inhibiting 
enantiomer. 
Although considered a non-COX inhibitor, R-FB has 
demonstrated chemoprotective activities in various animal 
models. In a 30-day study with R- and S-FB (McCracken et 
10 
 al. 1996), large bowel epithelial cell proliferation rates 
in laboratory rats were measured by labeling the crypts Of 
Lieberkiihn with bromodeoxy uridine (Brd-U) immunostaihing. 
In this study both R- and S-FB at 6.3 mg• kg"^•day"^ 
significantly reduced the percent of S-phase cells, when 
compared to the control animals given vehicle alone 
(1% CMC, carboxymethylcellulose). This study also 
demonstrated that S-FB is linked to ulcer formation, which 
is believed to be due to its COX inhibiting properties. 
There was an ulcer area approximately 20 times larger with 
S-FB than with R-FB. Although the ulcer area of R-FB was 
greater than that found with vehicle control (which 
exhibited no ulcers), the amount of ulceration was minimal. 
This minimal ulceration may have been the result Of S-FB 
formation via a process called epimerization or 
bioinversion, which is an enzymatic conversion of one 
enantiomer into the other (Wechter 1994). Because rats 
bioinvert R- to S-FB at a rate of 6 to 10%, there may have 
been enough S-FB present in these experiments to cause 
ulceration. However, in human clinical trials with R-FB, 
the rates of bioinversion to S-FB have beenrfound to be 
minimal (< 0.5 % bioinversion) at doses greater than 
11 
1200 mg day ^  and these have been associated with minimal GI 
toxicit:es (Quiggle et al. 2000). 
R-Flurbiprofen 
The minimal side effects of R-FB clearly give it an 
advantage over other NSAIDs. To evaluate the effectiveness 
of R-FB in preventing intestinal adenoma formation, a 
multiple intestinal neoplasia (Min/+) mouse model was used. 
The Min/+ mouse is heterozygous for a nonsense mutation in 
the APC gene and serves as a murine model for the human 
disease familial adenomatous polyposis (FAR) (Moser, Pitot 
and Dove, 1990; Su, et al. 1992). Weanling Min/+ mice 
(30 days old) given doses between 2.5 and 
25 mg R-FB•kg~^•day~^ for 6 weeks, exhibited a dose-dependent 
inhibition (40% to 90%) of adenoma formation (Wechter et 
al. 199"^). In these studies, mice bioinverted R- to S-FB 
at 6.9% and 16.6% in the 2.5 and 25 mg R-FB* kg"^* day~^ dose 
groups, respectively. At lower doses (<20 mg*kg~^*day~^) the 
amount of S-FB was minimal and resulted in little 
ulceration or other side effects. However, at higher doses 
(>20 mg* kg"^*day~^) bioinversion was significant (16.6%) and 
resulted in increased ulceration. These toxicities 
resulted in 35% of the animals dying from causes associated 
12 
with S-FB toxicity. Because mice exhibit higher R- to S-FB 
bioinversion rates, S-FB concentrations equivalent to those 
due to R- to S- bioinversion were tested in the Min/+ mice 
to determine if the activity of S-FB causes tumor 
inhibition. This study found that the R-FB inhibition of 
tumor formation could not be attributed entirely to the 
R- to S-FB bioinversion (W.echter et al. 1997). 
A study that supports the potential use of R-FB as a 
chemotherapeutic agent for preexisting tumors was performed 
using the Min/+ mice. In this study the mice were allowed 
to develop tumors, leaving, them untreated until 72 days of 
age [tumor loads are approximately 25 tumors/mouse in 
control groups; historical data (Wechter et al. 1997)]. At 
that point, the mice were treated with 10 mg*kg~^*day~^ R-FB, 
which had previously proven to be the optimal dose. These 
mice were treated for six weeks and then intestinal tumors 
were quantified. There was.a significant inhibition (85%) 
of tumors in the treated group, when compared to the 
control group (.1% CMC).' The average tumor load of treated 
animals were approximately 4 tumors/mouse while the control 
group had approximately 29 tumors/mouse. This study 
indicates that R-FB can possibly be used not only as a. 
:■ ■ 13-
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chemopreventive agent but also as a chemotherapy to 
eliminate and reduce existing colon tumors. 
I , . ; . 
JnI vitro studies involving cancer cell lines and 
various NSAIDs (i.e. aspirin, naproxen, indomethacin and 
piroxicam) have displayed an IC50 for proliferation ranging 
between 100 to 600 pM (Shiff et al. 1996). These NSAIDs 
(with the. exception of aspirin) also initiate apoptosis in 
the tested colon cancer cells (Shiff et al. 1996). To 
determine if R-FB was also active in vitro, experiments 
were performed on the colorectal cell line LS174T. In 
performing proliferation analyses an IC50 for proliferation 
was obtained at approximately 600 pM R-FB. Electrophoretic 
profileL of DNA from LS174T cells exposed to R-FB for 
24 hours revealed DNA laddering, a characteristic of 
apoptosis (Quiggle, unpublished data). The ability of R-FB 
I . , 
to induce apoptosis in vitro, may indicate the method in 
which it,acquires its chemopreventive and chemotherapeutic 
activities in in vivo studies. 
R-flurbiprofen has also been implicated in NF-kB 
inhibition. In vitro studies involving lipopolysaccharide 
(LPS) induced NF-kB activation have demonstrated that R-FB 
inhibits NF-kB activation (Tegeder 2000). This study 
14 
demonstrated that R-FB.inhibits the LPS-induced nuclear 
translocation of NF-kB, consequently blocking DNA binding. 
and inh biting NF-KB-dependent gene expression. The ability 
of R-flurbiprofen to inhibit NF-KB, may explain the 
apoptosis-inducing and anti-inflammatory activities 
associated with this drug. 
Study Objectives 
Although past"studies have demonstrated that R-FB was 
effecti"*re at inhibiting and eliminating colon tumors in the 
Min/+ mouse model, the rate and mode of eliminating 
existing tumors remains unknown. (Wechter et al. 2000 and 
Wechter et al. 1997). The purpose of this study was to 
study the pharmacodynamics of R-FB on tumor regression in 
Min/+ m;ce. The following pharmacodynamic parameters were 
evaluated in response to R-FB treatment: 1) the incidence 
of apoptosis in the normal appearing crypt and villus 
regions; 2) the incidence of apoptosis within tumors; and 
3) the 2 ate at which the number of tumors decreased. 
Understanding R-FB pharmacodynamics in reducing tumor 
number dan further test its potential as a chemotherapeutic 
agent and to aid in the design of future studies by 
optimiz ng for length of, treatment and timing. Although 
15 
understanding the .mode by. which tumors regress could help 
support in vitro work conducted.with R-FB, it could also 
help determine potential biomarkers for use in future 
animal and human studies.. Biomarkers from relatively small 
samples can be used as intermediate indicators of 
effecti/eness in cancer prevention and treatment studies, 
Biomarkers are especially important in human 
chemopreventive studies due to the constraints and 
longevi:y of human studies. 
Study Design 
The design of the proposed study was to administer 
R-FB to 72-day old Min/+ mice for up to 42 days. In order 
to capture the process of tumor reduction, animals were 
necropsied at various time points. At each time point 
animals were evaluated for tumor loads and presence of 
apoptotic cells along the small intestine.. Apoptotic cells 
were assessed using a terminal deoxynucleotidyl 
transferase-mediated dUTP-digoxigenin nick end labeling 
(TUNEL) assay.. Apoptotic indexes from the middle, to distal 
section of small intestines were determined in the crypts 
and. viltLi of normal appearing tissue and of tumor regions. 
16 
study L. mitations 
A foreseeable limitation Of this, experiment was the 
ability to obtain sufficient number of.histologic samples 
of tumor regions in animals treated with R-FB. This was 
due to the anticipated decrease in the tumor load of the 
animal. However, to increase the probability of obtaining 
a histological sample containing a cross-sectioned tumor. 
samples were cut at several places throughout the evaluated 
region. This was believed to give a sufficient number of 
observations in order to be statistically evaluated. 
17 
 CHAPTER TWO 
MATERIALS AND METHODS 
Materials 
Animals 
Fx ty-four weanling female C57BL/5J-APC'^^'^/+ mice 
26-32 days of age were obtained from Jackson Labs 
(Bar Harbor, ME). They were housed in the Loma Linda 
Animal Care Facility with,a 12-hour-on:12-hour-off light 
cycle.aifid controlled for humidity (50%) and temperature 
(72°F) The animals were given tap wafer and pelleted chow 
(AIN-93G, Dyets, Bethlehem, PA) ad libitum. . 
Chemicals 
R-Flurbiprofen (R-FB) (99% purity; >99% enantiomeric 
excess) was provided by Wycoff Inc. (Lot# 18AZ26C). All 
Other chemicals were commercially available from Fisher 
Scientific, with purity of reagent grade or better. 
Drug Preparation 
The R-FB was prepared as a suspension in 
1% carb Dxymethylcellulose, (CMC) by homogenization with a 
tissue idmogenizer, then heating to 60°C for approximately 
15 minutes, followed by rehomogenization. The amount of 
drug pr ipared was based on a dose volume of 1.0 ml-0.3 kg 
18 
and the daily dose of 10 mg-kg"^-day"^ (final concentration 
of the suspension was 3.0 mg R-FB*nil~^ in 1% CMC). 
Carboxymethylcellulose (1% CMC) was used as the vehicle 
control 
Methods 
Study Design 
R-Flurbiprofen Administration. Upon arrival, AVID 
microchips (AVID Identification Systems, Inc., Norco, CA) 
were inserted subcutaneously into the mice for 
identification purposes. The mice were then randomly 
assigneql into R-FB and vehicle-treated groups (6 mice per 
group) for each treatment time period (0, 4, 10, 21 and 42 
days; with the exception of day-0, which only consisted of 
a control group) by the Monte Carlo method (Niederreiter 
1992). Following randomization, the mice were fed only the 
AIN-93G diet until 72 days of age. Once aged, treatment 
began and all mice were administered drug or vehicle on a 
daily basis, by oral gavage. All mice were weighed weekly 
and the dosage was recalculated accordingly. 
Necropsy. After the completion of the designated 
treatment periods, the animals were necropsied. Necropsies 
were performed 2 hours after the animals last administered 
19 
dose. At necropsy, the mice were anesthetized by an 
intraperitoneal (i.p.) injection of 50-mg-kg~^- ketamine and 
10-mg•kg~^•xylazine solution. Following the midline 
abdominal incision, exsanguination via cardiac puncture was 
performed with a heparinized syringe. From the blood 
obtained, the hematocrit was determined and a 500 pi 
aliquot was set aside on ice for determination of plasma 
drug levels (see below). The animals were then 
disemboweled between the stomach and rectum and the 
intestinal tissue was processed as described below. 
Analysis of Plasma Drug Levels. Whole blood obtained 
2 hours after the last administered treatment was used for 
determining plasma drug levels. Plasma was obtained by 
centrifugation (13,000 x g for 5 minutes) of the whole 
blood. An aliquot of 100 pi was acidified with 20 pi of 
2 M HCl and vortexed for 30 seconds. To the acidified 
solution, 2.0 ml of a ice-cold hexane:ether (4:1) solution 
was added, followed by 3 minutes of vortexing. The organic 
and aqueous layers were separated by sonication (to reduce 
emulsification) and centifugation (13,000 x g for 
15 minutes). A 1.5 ml aliquot of the organic layer was 
removed and placed into a clean tube and allowed to air 
dry. 
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Once dry, the residue was dissolved in 150 yl of a 
hexane:isopropanol:acetic acid (97:3:0.5) solution of which 
100 pi v/as analyzed by high performance liquid 
chromatography (HPLC) analysis. The HPLC analysis was 
conducted on a Beckman System Gold Chromatography System 
(version 5.1) running on a PC-compatible computer. The 
dissolved plasma residue was applied to a S,S-Whelk-0 
column (4.6 x 250 mm; Regis Inc., Morton Grove, XL), and 
was eluted with a hexane:isopropanol:acetic acid (97:3:0.5) 
solution at 1 ml per minute for 15 minutes. The eluent was 
monitored at 254 nm. Standard curves were obtained by 
adding rac-FB to 200 pi of mouse whole blood over a range 
of 1-40 pg ml"^ of blood. The plasma was analyzed as 
described above. 
De :ermination of Tumor and Ulcer Load. For 
determination of total tumor load, the gastrointestinal 
tract was isolated. The three small bowel segments were 
excised as the proximal 4 cm (duodenum), the middle 4 cm 
(jejunum), and the distal 4 cm (ileum). These sections 
were cut longitudinally, washed with PBS (137 mM NaCl, 3 mM 
KCl, 4 iriM Na2HP04, and 1.5 mM KH2PO4, pH 7.1) and mounted on 
bibulous paper with the mucosal side up. These segments 
were fixed for approximately 24 hours in 10% neutral 
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buffered formalin (Fisher cat# HC-200-1 GAL) then 
transferred into a 70% ethanol (EtOH) solution until 
analysis. 
Tumors and ulcer.loads were determined independently 
by two observers in blind analysis. The segments were 
soaked in 0.05% aqueous methylene blue (Sigma-Aldrich) for 
approximately 10 minutes and then viewed with an Olympus 
SZH darlc-field stereomicroscope at a, constant, magnification 
(20X). After tumor identification (Figure lA), the tumor 
diametej: was obtained by measuring the tumor at its widest 
point. Measurements were taken using an eyepiece reticle 
that was standardized to a stage micrometer. The smallest 
measurable tumors were approximately 0.2 mm in diameter. 
Tumor areas were calculated as: area = [ti(diameter/2)^]. 
Average tumor area was obtained by taking the average of 
all tumor areas for each animal then reporting the average 
of each group. The tumor number reported was- the average 
of the total number of tumors counted from all the segments 
(proximal, middle and distal) for each animal. Ulcers were 
identified as non-raised areas, devoid of any villi 
exposing underlying mucosa, and encircled by tightly bound 
abnormal appearing villi. The ulcer number reported was 
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Figure 1. Small intestine tumors and villus stained for 
apoptosis in C57BL/6J-APC"^"/+ mice aged to 72 days old then 
administered R-flurbiprofen orally for Up to 42 days. 
the average of the total number of ulcers counted for each 
individual animal. . 
Tissue Preparation and Analysis 
Tissue Histology. The remaining segment of the 
middle-distal small bowel was, washed with PBS to thoroughly 
23 
clean the mucosa of any debris. This section was then cut 
into 3 to 4 equal portions which were mounted in parallel . 
position on porous tape and rolled up to maintain straight 
intestinal segments. The intestinal segments were then 
fixed in 10% neutral buffered formalin for approximately 
24 hours and then transferred into a 70% EtOH solution for 
24 hours. The segments were dehydrated by incubating in a 
series of solutions (70% EtOH, 90% EtOH, 95% EtOH, 10!0% 
EtOH, xylenes and then a 1:1 xylenes-paraffin solution) for 
two 30-minute incubation periods in each solution. After 
the dehydration steps, the segments were embedded 
longitudinally into paraffin and stored until sectioned. 
Apoptotic Cell Detection. A microtpme (RMC MT-920) 
was used to cut 4 am sections from the paraffin embedded 
intestinal samples. Cut sections were floated in a warm 
water bath then placed onto aminoalkylsilane treated slides 
(Polysciences, Inc, Los Angeles/ OA), to aid in tissue 
attachment. Slides were then placed in a 55° C oven for 
5 minutes then allowed to cool to room temperature. The 
slides were then dewaxed and rehydrated.by incubating../in a 
series of solutions (xylenes, 100% EtOH, 95%■EtOH, 
90% EtOH, 70% EtOH and PBS) for two 5-minute incubation 
periods in each solution. The TUNEL assay was performed 
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 utilizing the TAGS 2 TdT^DAB In Situ Apoptosis Detection 
Kit (Travgen Cat # , 4810-^30K). The tissue samples were"then 
exposed for 30 min to 7,5-pl of Cytopore™, (saponin-based 
permeab lization and blocking agent; Trevigen). Each slide 
was washed twice for 2.minutes in deionized water. Mucosal 
endogenous peroxidase enzymes were inactivated by soaking 
the slides in a 3% hydrogen peroxide-methanol solution for 
5 minuteis, then washing them in PBS for 1 minute. The 
tissue amples were immersed in a TdT labeling buffer 
(IM TACS Safe-TdT buffer, 0.5 mg ml^^ BSA, and 0.6 mM 
2-mercaptoethanesulfonic acid; Trevigen) for 5-minutes. 
Excess buffer was removed from the slides by blottingi 
around the tissue samples. A,50 pi volume' of labeling 
reaction mix [5 pM Biotinylated dNTP mix, IX Mn^"^ cation 
solution, TdT enzyme (cat# 4810-30-05; Trevigen).] was added 
and incubated for 60 minutes at 37°C in a humidified 
chamber. The reaction was stopped by immersing the slides 
in a TdT stop buffer (10 mM EDTA, pH 8.0 in deionized 
water) for 5 minutes and washing each twice in PBS for 
2 minutes. Tissue samples were incubated at room 
temperature for 10-minutes in 50 pi of a Streptavldin-HRP 
(horseradish peroxidase) solution in PBS, then washed twice 
in deionized water for 2 minutes each. Each slide was 
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immersed in DAB solution (Diaminobenzidine, 0.03% hydrogen 
peroxide, in PBS) for 2 minutes then washed twice in 
deionized water for 2-minutfes, The slides were 
Gounterstained with Methyl Green (1.0% Methyl. Green in 
0.1 M sodium acetate, pH 4.0) for 10 minutes and then 
dipped 10 times sequentially into deionized water, 
95% EtOH:, 100% EtOH, and 100% xylenes. The tissue samples 
were then mounted under glass cover slips using Permount® 
(Fisher Scientific, cat# SP15-500) mounting media. 
Identification and Counting of Apoptotic Cells. An 
observer (blinded to treatment) counted normal and 
apoptotic cells from 50 half-crypt (from bottom to top on 
one side of a crypt) and 50 villus regions (from top to 
bottom on one side of the villus) for each mouse. A 
0.15 mm^ area (estimated to contain 3000 cells) was counted 
for each tumor region (if present up to 10 tumor regions 
were counted). The apoptotic Index (AI) was defined as the 
total number of apoptotic cells divided by the total number 
of cells counted per region, multiplied by 100. 
Morphological traits such as condensed nuclei and cellular 
shrinkage were taken into consideration in conjunction with 
the biochemical assay used to confirm apoptosis. However, 
in most cases, normal cells were identified by the presence 
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 of a dark blue nucleus and light colored cytoplasm, while 
apoptotic cells were identified as having a dark brown 
nucleus and clear to light blue cytoplasm (Figure IB). 
Necrotic cells were identified as having a dark brown 
nucleus and light to dark brown cytoplasm. 
Statistical Analyses 
Descriptive analyses were applied to find the mean and 
standard deviation for the represented data. Descriptive 
statistics were performed on all data using the Kolmogorov-
Smirnov Test to test for normal population distribution and 
Levene Statistic to test for homogeneity of variance (SPSS® 
Base 9.0 Applications Guide. [1999]). For normal 
distributed data (all data with the exception of AI for 
tumor regions, fused villi and ulcer), ANOVA was applied. 
If the ANOVA test was found to be significant (p < 0.05), 
the multiple comparisons test of Games-Howell was applied 
with a significance of p < 0.05 (SPSS® Base 9.0 Applications 
Guide. [1999]). For nonparametric data (only AI for tumor 
regions, fused villi and ulcer), the Kruskal-Wallis Test 
was applied (SPSS® Base-9.0 Applications Guide. [1999]) If 
this test .was found to be significant (p < 0.05), the Mann-
Whitney test was applied with a 2-tailed significance of p < 
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0.05. For comparisons not significantly distinguishable by 
either ANOVA or Kruskal-Wallis, no further analysis was 
performed. Analyses were performed using SPSS for Windows 
(Release 9.0.0 [18 Dec 1998]). 
28 
CHAPTER THREE 
RESULTS 
Safety and Tolerance 
Dose To erability 
Overall the mice tolerated the administration of R-FB 
well. However, as expected signs of anemia (pale-looking 
muzzle and paws) were observed in the Day-42 vehicle-
treated group and this was supported by decreased 
hematocrits (HOT) measurements taken at necropsy. The 
vehicle treated groups showed stable HOT of approximately 
35%, up to Day-21 of treatment (93 days of age) relative to 
the Day-10 vehicle-treated group (Table 1). ,However, the 
HOT for the Day-42 vehicle-treated group decreased by 
approximately 25% when compared to the previous groups. On 
the other hand, the HCTs for the R-FB treated groups 
increased throughout most of the study and by day 42 had 
increased to approximately 40% from the Day-0 vehicle-
treated.group and approximately 75% from the Day-42 
vehicle-treated group '(Table 1). 
Drug Bioinversidn 
To determine plasma drug levels in the mice, blood was 
collected at the approximate Cmax (maximum plasma drug 
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Table 1. Tolerability of R-Flurbiprofen Administered 
Orally l:or up to 42 Days in C57BL/6J-APC'*^^"/+ Mice Aged to 
72 Days Old. 
% Change
HCT R-FB' S-FB' Bioinversion^ 
Treatment B. Wt^ . (%) (|ig-ml ({xg*ml-1 (%) 
Day 0 
None 33 ±8 0 + 0 ND ND 
Day 4 
VC 35 + 6 2 ± 1 ND ND 
R-FB 34 + 5 0 ± 1 50 ±19 3 + 0.2 5 ± 0.5 
Day 10 
VC 35 + 4 1 ± 2 ND ND 
R-FB 38 ± 5 2 ± 2 68.+ 11 7 ±2 9 + 1 
Day 21 
VC 36 ± 6 7 + 2 ND ND 
R-FB 43 ± 2 3 + 3 48 + 5 .3 ± 1 5 + 2 
Day 42 
VC 26 + 9 6 ± 8 ND ND 
R-FB 46 + 1^ 10 ± 3 55 ± 5 3 + 1 6 ± 1 
All groups contained 6, animals (except Day 42, R-FB 
treated group had 5 due to 1 death). 
^ P < 0,05 compared to treatment control. 
* Values given as mean ± SD. 
% Change B. Wt = Percent change in body weight = (ngcropsy 
weight - day-0 weight)/day-0 weight•100. 
R-FB = R-flurbiprofen. 
S-Fb - S^flurbiprofen. 
VC = Venicle Control (1% carboxymethylcellulose). 
HCT = Hematocrit. 
ND = None Detected. 
Bioinvetsion = S-FB(jxg•ml"^)/[R-FB (|J,g'ml"^)+ S-FB (|j,g ml"^)] 
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concentration) of R-FB. Overall the levels of R-FB were 
within previously reported values (Wechter et al. 1997). 
Because mice are a bioinverting species, concentrations of 
S-FB between 3 and 7 pg ml~^ correspond to approximately 5 
to 9% bioinversion (Table 1). 
Animal Deaths 
One death occurred 35 days into treatment in an animal 
scheduled to be treated with R-FB for 42 days (Table 1). 
Prior to death, the animal demonstrated normal behavior, 
weight gain, and no physical signs of morbidity. This 
animal was found dead in its cage probably due to 
iatrogenic effects during the administration of oral 
gavage, 
Pharmacodynamics 
Tumor Evaluation 
Tumor loads for individual animals decreased with time in 
the R-FB treated animals. The R-FB treated groups had 
fewer total tumor numbers after 10 days of treatment and by 
days 21 and 42 of treatment the tumors number was 
significantly less by approximately 70% and 87% (p < 0.05), 
respectively (Table 2). In the control animals, the tumor 
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 Table 2. Tumor Counts Evaluated in C57BL/6J-APC'^'^'^/t 
Mice Aged to 72 Days Old then Administered R-
Flurbiprofen Orally for Up to 42 Days. 
„ , , § _ Tumor Tumor Area"^ 
Treatment Tumor # ^, ^ t , > , 2% 
Diameter (mm) (mm ) 
Day 0 
None 24 + 18 0.7 ± 0.13 0.5 ± 0.17 
Day 4 
VC 26 ± 18 0.7 ± 0.13 0.6 ± 0.24 
R-FB 27 ± 8 0.5 + 0.07 0.3 ± 0.11 
Day 10 
VC 26 ± 16 0.7 ± 0.10 0.6 ± 0.17 
R-FB 16 ± 7 0.5 ± 0.07^ 0.2 ± 0.08^ 
Day 21 
VC 25 ± 7 0.8 ± 0.08 0.8 ± 0.10 
R-FB 7 ± 2^ 0.5 + 0.14^ 0.2 ± 0.15^ 
Day 42 
VC 27 ± 10 1.0 + 0.21 1.2 ± 0.49 
R-FB 4 ± 2^ 0.4 ± 0.25^ 0.2 ± 0.24^ 
^ All groups contained 6 animals (except Day 42, 
R-FB treated group had 5 due to 1 death). 
^ P < 0,05 compared to treatment control. 
^ Values given as mean ± SD. 
VC = Vehicle Control (1% CMC). 
R-FB = R-flurbiprofen. 
number remained stable at approximately 25 tumors per 
animal for all treatment periods. 
Treatment also influenced the size of the tumor. 
Tumors from the Day-4 R-FB treated groups decreased in the 
average tumor diameter by about 25% compared to the Day 0 
control group (0.5 ± 0.07 mm vs. 0.7 ± 0.13 mm), and 
maintained an average diameter of approximately 0.5 mm 
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throughout the 42 days of treatment. , The tumor diameters 
of the vehicTe-treated groups grew approximately 25% by day 
42 of treatment (0,75 mm ± 0.13 at day 0 to 1.05 mm + 0.21 
at day 42). Since■the tumor diameters were, less in the 
R-FB treated animals and greater in the vehicles-treated 
groups, a significant difference (p < 0.05) of approximately 
25% was established by Day-10 of treatment and had 
increased to 38% and 55% by 21 and 42 days of treatment, 
respectively. Analysis of the data obtained from both 
observers revealed no significant inter-Observer variance. 
Gastrointestinal observations described as ulcers were 
found in the early portion of this study (Table 3) . These 
ulcers were found predominantly in the R-FB. treatment 
groups, with the majority occurring at Day-10 of treatment 
and none being found at Day-42 of treatment. No ulcers 
were found in the vehicle-treated groups, with the 
exception of one animal with one ulcer. Fused villi were 
found only in the treated groups, with the exception of one 
animal in the Day-10 vehicle-treated group. The Day-21 
R-FB treated group contained the most fused villi, while 
the Day-4 treated group had none. However, fused villi 
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Table 3. Small Intestinal,Observations in 
C57BL/6J-APC"^"/+ Mice Aged to 72 Days Old. then 
Administered R-Flurbiprofen Orally for Up to 
42 Days. 
Fused 
Treatment Villi^ Ulcers'' 
Day 
Nor N.O. N.O. 
Day 4 
VC N.O. N.O. 
R- B N.O. 2 ± 2 
Day 10 
VC 0.3 ± 0.8 0.2 ± 0.4 
R-]B 3 ± 3 + 4 + 3 + 
Day 21 
VC N.O. N.O. 
R-FB 7, ± 3 + 2 ± 2 ^ 
Day 4 
VC N.O. N.O. 
R-FB, 5 ± 4 N.O, 
^ All g oups contained 6 animals (except Day-
,42, R-FB treated group had 5 due to 1 death), 
^P < 0 05 compared to treatment control. 
* Values given as mean ± SD. 
N.O. = No Observations, 
VC = Vehide Control (1% CMC). 
R-FB = R-flurbiprofen. 
were found from day 10 through day 42 in the R-FB treated 
groups 
Apoptotic Index 
When R-FB was administered, the apoptotic index for the 
crypts of Lieberkuhn sharply increased (Table 4). A 
significant two- to three-fold increase in the crypt 
apoptotic index was observed in the R-FB treated groups 
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Table 4. Apoptotic Index and Cell Positions of the Crypt, 
Villus and Tumor Regions in C57BL/6J-APC^^^/+ Mice Aged to 
72 Days Old then Administered R-Flurbiprofen Orally for Up 
to 42 Days. 
Treatment 
Treatment 
Length 
(days) 
N 
Apoptotic Index^ 
(%) 
# Cells/ 
Half-Region^ 
Crypt Region 
None 0 6 ±0.93 13.6 +0.8 
VC 4 6 0.71 ±0.51 13.8 ±1,0 
R-FB 4 4 ±0.571 14.1 ±0.5 
VC 10 4 1.30 +0.50 12.7 +0.2 
R-FB 10 1 3.73o 15.0 
OC 
VC 21 6 0.55 ±0,45 14.2 ±0,4
o 
R-FB 21 6 1,98 ±0.68^ 13.0 ±0.8 
NC
OVC 42 6 ±0.79 13.5 ±0.8 
CO 
R-FB 42 5 2.90 ±0.32*'^ 12.8 ±0.6 
Villus Region 
Non(e 0 6 0.39 ±0.29 34.1 ±1.7 
VC 4 6 0.23 ±0.12 35.4 ±1.9 
r-f: 4 4 0.30 ±0.17 34.9 ±2.1 
VC 10 4 ^ 0.2'2 ±0.24 35.6 ±3.8 
R-FB 10 1 0.22 36.7 
VC 21 6 0.27 ±0.20 35.8 ±2.3 
R-FB 21 6 0.95 ±0.51 31.0 ±1.6' 
VC 42 6 0.39 ±0.28 34.8 ±2.8 
R-FB 42 5 0.85 ±0.53 33.4 ±2.5 
Tumor Region 
None 0 5 0.11 ±0.06 
VC 4 6 0.08 ±0.02 
R-FB 4 1 0.12 
VC 10 3. 0.12 ±0.04 
R-FB 10 0 
VC 21 6 0.08 ±0.03 
R-FB 21 3 0.29 ±0.22 
VC 42 6 0.08 ±0.03 
R-FB 42 2 0.52 ±0.58 
P < 0,05 compared to day 0 control. 
P ^ 0.05 compared to treatment control. 
Values given as mean i SD. 
VC = Vehicle Control . (1% CMC). N = Sample number 
R-FB '= R-flurbiprofen. 
Apoptotic Index = # apoptotic cell/[# normal cells 
# apoptotic cells]*100. 
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compared to the vehicle-treated groups and was maintained 
throughoiut the study. However the increase in the 
incidencie of apoptotic cells did not result in a change 
in the mumber of cell positions lining the half-crypt 
(Table 4). 
The apoptotic index of the villus region did not match 
that of the crypt region. There was no difference in the 
apoptoti.c index between the R-FB treated groups and the 
vehicle-treated groups. The number of cell positions 
lining the half-villus also remained unchanged between the 
vehicle and R-FB treated groups, with the exception of the 
Day-21, groups. The Day-21 R-FB treatment group showed an 
apoptotic index decrease of approximately 13% compared to 
the vehicle-treated group. However, this difference was 
not easily explained relative to the other R-FB treated 
groups, since they did not demonstrate any change in the 
apoptotic index. 
The apoptotic index of tumor regions proved to be a 
difficult measurement to obtain. Because of the spacing of 
tumors and the reduction of tumor number in R-FB treated 
animals the task of obtaining a slide section that bisects 
a tumor was very difficult and influenced the number of 
animals that were evaluated for tumor AI. Although there 
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appeared to be a large increase in the apoptotic index of 
Day-21 and Day-42 treated groups, the small and unequal 
sample size severely affected statistical validation of 
comparisons and prevented its analysis. 
The multi-step process to prepare the samples for 
TUNEL was vital to properly assess for apoptotic cells. 
For an unidentified reason, the majority of the Day-10 
animals could not be assessed because the paraffin embedded 
tissue samples were either too fragile or brittle and,were 
unable :o withstand the TUNEL assay procedures 
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CHAPTER FOUR 
DISCUSSION AND CONCLUSION 
Discussion 
Previous studies have shown that when R-flurbiprofen 
was administered in the Min/+ mouse model it caused the 
prevent!on and regression of Min/+ tumors. This study 
addresses the issue of the rate at which these tumors 
regress and mode of action. The data obtained from this 
study demonstrate that R-flurbiprofen.administration in the 
Min/+ mouse model caused: 1) a time-dependent decrease in 
the total .number of developed tumors; 2) some involvement 
of increasing apoptosis in tumor regions, 3) a significant 
increase of the AI in normal appearing crypts of the small 
intestine, and 4) no change in the AI of normal appearing 
villus j-egions. Previous studies involving other NSAIDs 
have demonstrated.rapid regression of tumors and increased , 
AI in only the villus region (Boolbol et al. 1996, Chiu, 
McEntee and Whelan 1997 and Mahmoud et al. . 1998). .Although 
this study was contradictory regarding the AI incidence, 
these results seem to be more rational based on GI 
epithel. al cellular kinetics. 
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Previous studies with R-FB in the Min/+ mouse model 
found approximately 70% to 9Q% tumOr inhibition after 42 to 
204 days of treatment (Wechter et al. 1997 and Wechter et 
al. 2000). In the current study, tumors decreased in 
number gradually beginning between days 4 and 10 of drug 
administration and continuing through day 42. The tumor 
regression observed was not as rapid as those exhibited in 
a similc.r study using sulindac, a potent COX-2 inhibitor of 
the acetic acid class of NSAID (Chiu, McEntee and Whelan 
1997). In the sulindac study, tumor loads were evaluated . 
for up to 20 days, and displayed a rapid regression of 
tumor number. There was a rapid time-dependent decrease in 
the tumor load of the sulindac treated animals. However, 
due to weak inhibition by R-FB of the COX enzymes, it was 
anticipated that a slower regression would have occurred. 
The assumption in this,study was that if R-FB affects 
tumor growth by stimulating apoptosis, the apoptotic index 
(Al) would increase in the tumor regions and slowly 
decrease the tumor size until the tumor was no longer 
present. Obtaining an Al for the tumor regions in all 
animals proved to be an difficult task. The AI's that were 
obtained were based on a small number of animals which were 
not large enough to perform statistical,analyses. However, 
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as hypothesized the average tumor diameter did not decrease 
over time but actually stayed relatively stable throughout 
the study in the R-FB treated animals (Table 2). This may 
indicate that the loss of single tumors happens over a 
relatively short time frame. One method of rapid tumor 
loss is when a whole tumor detaches from the wall of the 
intestine and is lost into the lumen of the intestine 
(desquamation), This concept was considered in the 
sulindac study mentioned above. Because of the rapid 
decrease in tumor counts and the inability to show an 
increase in AI in the tumor regions, however those authors 
also had difficulties with obtaining AI's (Chiu, McEntee 
and Whelan 1997). One piece of evidence that suggests 
that desquamation may occur was one histological slide of_ 
the small intestine of an R-FB treated animal (Figure 2). 
The arrow points to a large mass of tissue within the small 
intestinal lumen with a large number (approximately 80%) of 
the cells undergoing apoptosis or necrosis. This 
observation was seen over several serial sections and was^ 
believed not to be an artifact of preparation. If these 
tumors did in fact undergo desquamation, this rapid process 
may leave behind an ulcer-like mucosa. 
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Figure 2. Small intestinal lumen from a C57BL/6J-APC ^"/+ 
/ 
mouse administered R-flurbiprofen orally. 
The observations of ulcers in this study were first 
thought to be the result of ulcer induction due to the 
small amount of bidinversion from R-FB to S-FB present in 
this model. However, it seems that the ulcer appearance 
may correlate better with tumor loss. The data show that 
over time, ulcers appear first during times of more rapid 
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tumor regression and they are absent at day 42, a time when 
tumor regression rate may be at its lowest. This 
correlaljion may indicate that desquamatioh of the tumors 
occurs, I leaving behind a region with ulcer-like appearance. 
The observation of'fused villi was believed to be the 
result if ulcers healing and this may still be the case.. 
Fused vlilli appeared after the presence of ulcers and were 
then present throughout the rest of the study. Although 
the sullindac study (Chiu, McEntee and Whelan 1997) had 
mentioied "crateriform lesions" (believed to be ulcers as 
described by this paper), they had never suggested that 
desquaiaation may be the cause. Although this study was not 
designid to study the correlation between tumor regression, 
ulcer jformation and fusion of villi these results warrant 
furthJr analysis and should be the. subject of additional 
studies. 
ihe AI was studied in the crypt and villus regions of 
normal appearing tissues. Although the villus showed no 
increase in AI over time, only the crypt region had a 
significant increase in AI throughout the study. This was 
the Ojpposite of what was seen in the sulindac studies 
(Boolbol et al. 1996, Chiu, McEntee and Whelan 1997 and 
Mahmcpud et al. 1998), which reported the AI increases only 
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in the tjbp portion of the villus region. In the present 
study tlrie AX of the crypt regions increased 2- to 5-fold 
more thj.n the vehicle-treated groups. These results are 
favorable, based on stem cell kinetics of the small 
intestilie. These stem cells reside in the crypt of the 
small intestine. The number of stem cells has a positive 
influenlce on the proliferation rate of the gastrointestinal 
epithelium. Studies suggest that the number of stem cells 
and thi apoptosis rate are vital in maintaining constant 
cell plpulations in of the gastrointestinal epithelium 
(Potteli, Wilson and Booth 1997 and Renehan, Bach and Potten 
2001). This is because one stem cell can produce hundreds 
of cells that migrate up the crypt and onto the villus. 
When the number of stem cells goes unchecked by apoptosis, 
tumorJgenesis can occur (Renehan, Bach and Potten 2001)., 
Therefore, the ability of R-FB to increase the incidence of 
apoptosis in the crypt opposed to the villus, gives greater 
suppojrt to its anti-tumor activities and as a potential 
therapeutic agent. 
As with any drug, safety and tolerance are important 
to the success of an efficacious chemotherapeutic agent. 
The current study has shown that those animals treated with 
R-FBIfor 42 days had improved hematocrits from that of Day-
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0 and Day-42 vehicle-treated animals. Hematocrits have 
proven tie be an important surrogate marker for tumor burden 
in the Min/+ mice. It is believed that as the tumor load 
increases, hematocrit is adversely affected over time. The, 
one death that was observed in this study was believed to 
be iatrLgenic in origin possibly during the administration 
of oral! gavage. Based on previous experience this is a 
rare yet expected consequence of drug administration by the 
use of oral gavage, especially in cases when no adverse 
observations were noted prior to the animal's death. Based 
on the I current study, along with human studies, it is 
further supported that R-FB is a safe and well tolerated 
drug t|L administer as a chembtherapeutic agent (Quiggle et 
al. 2o|oO). 
Conclusion |n conclusion, the data obtained from Min/+ mice 
administered R-flurbiprOfen, demonstrated: 1) a steady 
decrease in the total number of developed tumors over time; 
2) soine involvement of increasing the AI in tumor regions, 
3) a jsignificant increase of the AI in normal appearing 
crypts of the small intestine, and 4) no change in the AI 
of nirmal appearing villus regions. Increased incidence of 
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apoptosis in the crypts of normal appearing tissue supports 
the tumor prevention activity of R-FB. Although there was 
some evidence of an increased incidence Of apoptosis in 
tumor regions there was not an overall decrease in tumor 
diameters. Because of this, the possible roles of apoptosis 
and des^uamation in tumor regression are still unknown. 
With a better understanding of the rate at which tumors , 
decreas|e in number with R-FB administration, future studies 
can be better designed to optimize the time frame in which 
to capture the process of tumor regression. 
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